CBGL (Cannabis Global) Equity-to-Asset: 0.22 (As of May. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cannabis Global Equity-to-Asset?

Cannabis Global CBGL Equity-to-Asset is 0.22 as of May. 2022.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cannabis Global's Total Stockholders Equity for the quarter that ended in May. 2022 was $3.21 Mil. Cannabis Global's Total Assets for the quarter that ended in May. 2022 was $14.91 Mil. Therefore, Cannabis Global's Equity to Asset Ratio for the quarter that ended in May. 2022 was 0.22.

The historical rank and industry rank for Cannabis Global's Equity-to-Asset or its related term are showing as below:

CBGL's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.61
* Ranked among companies with meaningful Equity-to-Asset only.

Cannabis Global  (OTCPK:CBGL) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Cannabis Global Equity-to-Asset Related Terms


Cannabis Global Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Cannabis Global's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannabis Global Equity-to-Asset Chart

Cannabis Global Annual Data
Trend Aug12 Aug13 Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.80 -27.00 0.28 -0.62 -0.20

Cannabis Global Quarterly Data
Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.20 0.05 0.23 0.22

CBGL vs MILC, BBBT, GCAN: Equity-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Global's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannabis Global Equity-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Global's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Cannabis Global's Equity-to-Asset falls into.



Cannabis Global Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Cannabis Global's Equity to Asset Ratio for the fiscal year that ended in Aug. 2021 is calculated as

Equity to Asset (A: Aug. 2021 )=Total Stockholders Equity/Total Assets
=-2.212/11.339
=-0.20

Cannabis Global's Equity to Asset Ratio for the quarter that ended in May. 2022 is calculated as

Equity to Asset (Q: May. 2022 )=Total Stockholders Equity/Total Assets
=3.213/14.909
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of 0.22 mean?
Cannabis Global (CBGL) has a Equity-to-Asset of 0.22 as of May. 2022. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cannabis Global and its competitors.
Is Cannabis Global's Equity-to-Asset too high?
Cannabis Global's current Equity-to-Asset is 0.22. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Cannabis Global's value of 0.22 is 63.9% below this industry median.
How does Cannabis Global's Equity-to-Asset compare to MILC and BBBT?
Cannabis Global's Equity-to-Asset of 0.22 can be compared against companies in the Drug Manufacturers industry. The industry median Equity-to-Asset is 0.61. Cannabis Global's value of 0.22 is 63.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannabis Global's current Equity-to-Asset of 0.22 is 63.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cannabis Global and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannabis Global's current Equity-to-Asset is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannabis Global stock overvalued right now?
Cannabis Global (CBGL) has a current Equity-to-Asset of 0.22. The current Equity-to-Asset is 0.22 and 63.9% below the Drug Manufacturers industry median of 0.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cannabis Global (CBGL), the current Equity-to-Asset is 0.22 as of May. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cannabis Global Business Description

Address 520 S Grand Avenue, Suite 320, Los Angeles, CA, USA, 90071
Cannabis Global Inc manufactures and distributes various cannabis products via its majority ownership of Natural Plant Extract, Inc is developing the Ethos Comply Bag, and generally conducts research and development in the areas of hemp, cannabis and consumer food goods. The company also have an active research and development program focused on creating and commercializing engineered technologies that deliver hemp extracts and cannabinoids to the human body. Its product includes cannabis flower packaged in various weights, cannabis Pre-rolls, cannabis edible products.